Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Stem cell stocks to get a boost, STEM....GERN
Frist to back funding of stem cell research
Senate majority leader to break with Bush on issue
Friday, July 29, 2005; Posted: 3:55 a.m. EDT (07:55 GMT)
Frist plans remarks on stem cell research when the Senate resumes business Friday.
WASHINGTON (AP) -- Breaking with President Bush, Senate Majority Leader Bill Frist has decided to support legislation to expand federal financing for embryonic stem cell research, raising the possibility Congress will enact such a bill, according to a Senate aide knowledgeable about Frist's plans.
Frist, who last month said he did not at this time support expanded federal financing of such research, was to explain his decision to now support such financing in a speech on the Senate floor Friday morning.
Frist plans to say that he will support the broader federal financing despite having reservations about disagreeing with Bush's policy that stringently limits taxpayer financing for stem cell research, said the aide, who spoke on condition of anonymity because of a reluctance to undercut Frist's formal announcement.
Frist, R-Tennessee, who is a cardiologist, could not be reached for comment late Thursday.
Bob Stevenson, the majority leader's spokesman, declined to comment beyond saying that Frist planned remarks on stem cell research when the Senate resumes business Friday.
Frist's decision was first reported Thursday by The New York Times on its Web site.
It quoted Frist as saying in the text of his planned speech that the limitations put in place by the Bush administration in 2001 on stem cell research "will, over time, slow our ability to bring potential new treatments for certain diseases."
"Therefore, I believe the president's policy should be modified," the newspaper quoted Frist, a surgeon, as planning to say.
Bush has threatened to veto legislation for expanded financial support for stem cell research.
A bill to finance more stem cell research has passed the House, but has been stalled in the Senate.
The shift in views could impact Frist's presidential prospects since it would put him in conflict with not only the White House but also Christian conservatives, whose support he has been courting.
The Times said that Frist, in his speech, will reaffirm his position on abortion and say he can reconcile his position on stem cell research with his anti-abortion views.
"I believe human life begins at conception," he is quoted as saying. "I also believe that embryonic stem cell research should be encouraged and supported."
In 2001, Bush announced his position on stem cell research, saying the government should pay only for research of stem cell colonies, or lines, that were created by that date where the "life or death" decision already has been made.
Copyright 2005 The Associated Press. All
Sam, they will get with the OTC program shortly:
VMHVF
NOTE 2 - COMMON STOCK
During the nine months ended March 31, 2005 the Company issued 241,000 shares of common stock for employee Christmas bonuses of $2,410; 190,000 shares of common stock for services of $7,500; issued 8,440,000 shares of common stock for consulting services of $197,000. The Company also issued 1,300,000 shares of common stock for expenses of $65,000 incurred for new web site development and 190,000 options were exercised for $9,025.
NOTE 3 - STOCK OPTIONS
On March 24, 2004, the Company's board of directors approved the VMH VideoMovieHouse.com 2004 Nonqualified Stock Option Plan. This plan, subject to the authorization of the Company's board of directors, allows the Company to distribute up to 5,000,000 options on common stock shares to officers, directors, employees and consultants at an exercise price of up to $0.25 per share.
On October 8, 2004 the board of directors approved an increase in S-8 stock to 15,000,000 options on common stock shares to officers, directors, employees and consultants at an exercise price of up to $0.03 per share.
F-6
Is this what's it like being up Sh*t Creek without a paddle?
Hope we get some news before the weekend (if all are finished buying at these levels).
Dilution killed FASC, it's overpriced at 4 cents. VMHVF hasn't got greedy yet, but they will if the pps stays up. At least they waited until they had a little revenue before going to the OTC.
VMHVF is doing better than DELL?
TRCPA, don't know why you didn't want to answer my question, but my point is: It may not be a good idea to make a big deal out of no change in the OS for a few months because that could change quickly! Maybe revenues are the reason or maybe they sold enough shares in prior months to meet the burn rate for a while or a combination of the two. It's not cheap to travel around the world and I don't think it's the intent of organizations like WRAP to provide profits, but at best to cover the expenses of those participating in the tests.
I'm still not 100% convinced that the OS is not going up, but the next filing will give the facts.
beigledog, nice run? Shares from 18 cents? You guys confuse me, if someone questions what if anything is going on to create revenue, you start talking about a run up in pps based just on hype. Where's the sales promised by the distributor? Was that all BS? Tons of clay being mined? So what, just research quanities of nano tubes? I just get sick of all the hype and bullschitt sometimes, that's all. I hope you get your 8 bagger.
wookiebookie, I was just kidding, I wasn't at the meeting and don't have a clue about the payment.
How much was the last revenue announced? I must have missed it!
Do they have to use a microscope and tweezers to get the nanotubes? Maybe that's why no real sales yet. From RB BIPH board:
By: blessed_joshua
27 Jul 2005, 08:54 PM EDT
Msg. 65515 of 65516
Jump to msg. #
I spoke with the President of NaturalNano about the seperation of Nano tubes. He stated to me that they have seperated some tubes out of the clay but only enough for Researchers.
Check is in the mail.....
ASPN closed up a buck today! Dang!
http://www.investorshub.com/boards/read_msg.asp?message_id=7115796
http://finance.yahoo.com/q?s=ASPN.OB&d=t
DANG! Did you guys say buy or sell???? Hope they get some news out SOON!
TDYH....
On the pinks now, but buy when it's on Amex if you want to pay more. )))))
XDSL $0.27 and LU, just saw this, XDSL might be worth a look:
mPhase Technologies Wins Spot Among Inaugural 'Nano 50' Innovators in Nanotechnology
Wednesday July 27, 8:56 am ET
Company Cited for its Smart NanoBatteries Under Development with Lucent Technologies' Bell Labs Unit
LITTLE FALLS, N.J.--(BUSINESS WIRE)--July 27, 2005--mPhase Technologies (OTC: XDSL - News) has been cited among the inaugural "Nano 50" of leading nanotechnology firms and individuals compiled by an independent panel of experts.
Under sponsorship of Nanotech Briefs, the digital magazine from the publishers of NASA Tech Briefs, a official engineering and design periodical of the National Aeronautics & Space Administration, the Nano 50 list of winning companies and individuals is described by the sponsors as "the 'best of the best' - the innovative people and designs that will move nanotechnology to key mainstream markets."
The winners will be honored at the Nano 50 Awards Dinner at Nano 2005, November 10-11, 2005, at the Boston Marriott, Newton, Mass.
mPhase was honored for its "Smart NanoBatteries" in the Technology category. The novel battery architecture is based on a discovery at the Bell Labs research and development unit of Lucent Technologies (NYSE:LU - News) that liquid droplets of electrolyte will stay in a dormant state atop microscopic structures called "nanograss" until stimulated to flow, thereby triggering a reaction producing electric current.
Future batteries based on this technology have the potential to deliver far longer shelf life and better storage capacity than existing battery technology. Potential initial applications for this technology may include defense, industrial, healthcare, and consumer electronics. mPhase is also targeting the nanobattery for use in a technically-improved, lighter weight battery designs.
This is the second major independent recognition this year garnered by mPhase for its nanotechnology leadership, having been awarded the 2005 Frost & Sullivan Excellence in Technology Award.
About mPhase Technologies, Inc.
mPhase Technologies Inc. (OTC: XDSL - News) develops and commercializes next-generation telecommunications and nanotechnology solutions, delivering novel systems to the marketplace that advance functionality and reduce costs. The company, awarded the 2005 Frost & Sullivan Excellence in Technology Award, is bringing nanotechnology out of the laboratory and into the market with a planned innovative long life power cell. Additionally, the company is working on prototype ultra-sensitive magnetometers that promise up to a 1,000-fold increase in sensitivity as compared with available uncooled sensors. More information is available at the mPhase Web site at www.mPhaseTech.com
Safe Harbor Statement
This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of the company in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the companies have no control.
--------------------------------------------------------------------------------
Contact:
TMI
Sam Gronner, 201-592-7896
sam@gronnerpr.com
--------------------------------------------------------------------------------
Source: mPhase Technologies Inc.
Long term buy and hold? Sun Micro (SUNW:Nasdaq - commentary - research) earned $121 million, or 4 cents a share, on sales of $2.98 billion in its fourth quarter. Adjusted earnings of 6 cents a share were 5 cents better than estimates. The company reported improvements in its book-to-bill ratio, product services backlog and its deferred revenue.
$3.85 close yesterday.
(clips from PR's)
And Sun has managed to maintain a sizable stockpile of cash and marketable securities -- now more than $7.5 billion.
Last month, it announced it would spend a large portion of that cash on two acquisitions it hopes will re-ignite growth.
"FY05 was a year of stabilized revenue and earnings," McNealy said. "Our opportunity for Y06 is sustained growth and profitability."
Following its usual practice, Sun did not release an earnings or sales forecast for the fiscal first quarter.
But Sun's president, Jonathan Schwartz, said the company would announce a major win with General Motors Corp. on Wednesday. The automaker will be deploying Sun's Java Enterprise System and Sun's Solaris 10 operating system. Terms of the deal and other details were not disclosed.
Good luck to all at the shareholder meeting today! Hope you get lots of info and have safe trips home!
OT: twojugglers, would you take 1000 FASC shares for the pitcher?
It's not a pill?
ASPN, another missed op, OTC oil and gas, on my watch list, up 125%, but never bought. TDYH will do better though, IMO.
Corning, GLW, good earnings.
http://biz.yahoo.com/rb/050726/tech_corning_earns.html?.v=1
DOR so-so today, CIGA way up today, then crashed on earnings after hours. This investing chit is hard work!
Doubloon one thing about "quiet period", some (within companies) misinterpret what is meant by "quiet period". They don't have to be 100% silent, they are permitted to PR as they would for normal business happenings.
Where do you stick that pill that lasts for several years? TIA.
I think VMHVF looks like MSFT, but not as big.
CNR also moving today, up 19%, but on CD financing news!
http://biz.yahoo.com/bw/050725/255972.html?.v=1
0.04 X 0.04! Tightest spread I've ever seen! LOL!
DOR, got filled at 0.35! Couldn't believe it! Now watch it drop! LOL!
Oh my, is DOR gonna pop? $0.31 close and PR on DOW division deal:
DOR BioPharma and Dowpharma Enter Into a Joint Development Agreement for BT-VACC, DOR's Oral Vaccine Against Botulinum Toxin Poisoning
Tuesday July 26, 7:30 am ET
MIAMI, July 26, 2005 (PRIMEZONE) -- DOR BioPharma, Inc. (AMEX:DOR - News) (``DOR'', or the ``Company'') today announced it has entered into a joint development agreement with Dowpharma(sm), a business unit of The Dow Chemical Company (NYSE:DOW - News), to advance the development of DOR's proprietary oral botulinum vaccine, BT-VACC(tm). BT-VACC(tm) is designed to protect against exposure to botulinum toxin, which is one of five Category A bioterrorism threats identified by the U.S. government.
Under the agreement, Dowpharma will provide process development leading to current Good Manufacturing Practices (cGMP) production services for BT-VACC(tm) using its Pfenex Expression Technology(tm), a Pseudomonas-based technology that accelerates speed to market for vaccines and biotherapeutics by surpassing the quality and yield capabilities of existing microbial systems.
DOR's BT-VACC(tm) is an orally administered vaccine that protects against exposure to botulinum neurotoxins. Oral administration of BT-VACC(tm) produces protective antibodies that afford protection or prolonged survival of treated animals against 30,000 times the lethal dose of botulinum toxin serotype A. The oral route of administration of a vaccine is believed to be preferable to the injectable form due to benefits derived from safer and easier administration, lack of skilled medical personnel needed for administration, and relative ease of distribution to the civilian population. DOR believes that it is the only company developing an orally delivered botulinum toxin vaccine. Recent preclinical studies of BT-VACC(tm) for serotype B resulted in similar immunogenicity and protective efficacy results. Ongoing studies at Thomas Jefferson University are focused on serotype E and multivalent immunization experiments using serotype A, B and E antigens given simultaneously to animals.
``This is an important relationship for us as we continue to develop BT-VACC(tm),'' commented Michael T. Sember, president and CEO of DOR BioPharma, Inc. ``Results to date indicate that BT-VACC(tm) has the ability to induce protective antibodies in appropriate animal models. With Dowpharma's Pfenex Expression Technology(tm), we intend to expedite the production of multiple botulinum toxin serotype antigens from the laboratory to cGMP production so that we can rapidly advance BT-VACC(tm) into the clinic.''
Dowpharma has an unmatched record in developing high-productivity strains for numerous protein products, for both clinical and industrial applications. Dowpharma has developed a Pseudomonas-based technology and know-how directed toward protein expression and downstream processing of expressed proteins and other biologically active compounds known as Pfenex Expression Technology(tm). Pfenex is built around specially modified strains of Pseudomonas fluorescens bacteria that increase cellular expression of recombinant proteins and peptides while maintaining critical solubility and activity characteristics.
``Dowpharma is committed to the development of biodefense products as this is our third program to address bioterrorism threats,'' said Nick Hyde, Business Director of Dowpharma. ``Pfenex is proven to improve protein production and consistently outperforms other commercially available microbial expression systems such as E. coli. We are honored to work with DOR to expedite the development of this important vaccine.''
Botulinum toxin is considered the most poisonous natural substance known to mankind and is classified as a Category A biothreat by the Centers for Disease Control (CDC). It is aerosolizable and has previously been used in a number of well-documented incidents. It is 100,000 times more toxic than sarin gas, and currently there are no FDA-approved vaccines or therapeutics. The toxin is known to exist in seven different serotypes, designated A to G, but only three (A, B and E) account for almost all human cases of disease. Once exposed to botulinum toxin, blockage of peripheral nerve function and descending flaccid paralysis occurs which ultimately leads to death within hours.
About DOR BioPharma, Inc.
DOR BioPharma, Inc. is a biopharmaceutical company focused on the development of therapeutic products and biomedical countermeasures for areas of unmet medical need. Our lead product, orBec(r) (oral beclomethasone dipropionate), is a potent, locally-acting corticosteroid being developed for the treatment of intestinal Graft-versus-Host disease (iGVHD), a common serious complication of bone marrow transplantation for cancer, as well as other gastrointestinal disorders characterized by severe inflammation. We intend to file a new drug application (NDA) with the FDA for orBec(r) for the treatment of iGVHD later this year.
Through our BioDefense Division, we are developing biomedical countermeasures pursuant to the paradigm established by the recently enacted Project BioShield Act of 2004. Our biodefense products in development are bioengineered vaccines designed to protect against ricin toxin and botulinum toxin, both of which are considered serious bioterrorism threats. Our ricin toxin vaccine, RiVax(tm), is currently the subject of a Phase I clinical trial in normal volunteers. We have also recently announced the initiation of a new botulinum toxin therapeutic development program based on rational drug design.
For further information regarding DOR BioPharma, please visit the Company's website located at http://www.dorbiopharma.com.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, that reflect DOR BioPharma's current expectations about its future results, performance, prospects and opportunities, including statements regarding the potential use of orBec(r) for the treatment of iGVHD and the prospects for regulatory filings for orBec(r). Where possible, DOR BioPharma has tried to identify these forward-looking statements by using words such as ``anticipates,'' ``believes,'' ``intends,'' or similar expressions. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. DOR BioPharma cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including orBec(r), particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its technologies will prove to be safe and effective (including that the results of its Phase I clinical trial of RiVax(tm) will demonstrate acceptable safety and immunogenicity/efficacy), that its cash expenditures will not exceed projected levels, that it will be able to obtain future financing or funds when needed, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the U.S. Government or other countries, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, that it will be able to maintain its listing on the American Stock Exchange, or that its business strategy will be successful. Important factors which may affect the future use of orBec(r) for iGVHD include the risks that: because orBec(r) did not achieve statistical significance in its primary endpoint in the pivotal Phase III clinical study (i.e. a p-value of less than or equal to 0.05), the FDA may not consider orBec(r) approvable based upon existing studies, orBec(r) may not show therapeutic effect or an acceptable safety profile in future clinical trials, if required, or could take a significantly longer time to gain regulatory approval than DOR BioPharma expects or may never gain approval; DOR BioPharma is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; or orBec(r) may not gain market acceptance; and others may develop technologies or products superior to orBec(r). These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, DOR BioPharma's most recent reports on Form 10-QSB and Form 10-KSB. DOR BioPharma assumes no obligation to update or revise any forward-looking statements as a result of new information, future events, and changes in circumstances or for any other reason.
Contact:
DOR BioPharma, Inc.
Evan Myrianthopoulos, Chief Financial Officer
(305) 534-3383
www.dorbiopharma.com
MDII, no debt according to Yahoo and 14M OS. Only 4% insider ownership, but I'm beginning to think that may be a good thing! Some of these security stocks with heavy insider ownership start dumping like crazy on spikes, maybe watch for some insider buying in the weeks ahead.
mcenulty, thanks for starting the board.
http://finance.yahoo.com/q/ks?s=MDII
MDII after hours!! Looks like homeland security is the hot sector right now. 14 million OS.
http://finance.yahoo.com/q?s=MDII
TRCPA, no, I think they find it "interesting", except for HAL, I don't think HAL cares if they use a KDS or a concrete mixer as long as the product meets their specs (as in product already shipped not processed by the KDS?) Again, I judge true interest in a company's products by the movement of the pps. Some of the homeland security companies now have lot's of "interest" in their products and their pps shows that (deserved or not). The FASC pps tells me all those on your list are not interested enough to be heavily buying FASC shares (emphasis on "heavily", tiny blocks on quiet buying don't count! LOL!)
Doubloon, sounds like it would get false readings from lawn fetilizer or dog poo. ISON's "suitcase-size detector" gets false readings from plastics (contained in most belongings/ luggage, of course).
starboy, I know how you feel, but I think we just have to wait it out. My feeling is we're not dealing with the typical pump and dump so prevalent on the OTC and pinks and Doubloon's info from the company makes a lot of sense. I'm believing the guys are for real and trying to get it done. We still have to consider it very speculative that they will get it accomplished, but that's the ball game. Let's keep our fingers crossed, sometimes that's all you can do at this stage. I'm down over half at this point and trying to decide if I want to add or just hold.
TRCPA, "ridiculous" fits well here, IMO, it's just my posts may be on the other end of the ridiculous scale. Like you always say, different strokes. For example, I think "share buy-back" is ridiculous, but others don't see it that way.
I guess C2C ZEOLITE CORP won't let them borrow the Bobcat anymore.
Is everyone FASC asleep?
Charlie! Where did you go? Are you OK? Volume sure is up from 1000 shares a day! 176,000 so far!
Volume up!!!!!!!!!!!!!! News coming?????????
AATK moving premarket, someone said gov contract on GEPT board, but I can't find news!
AATK chemical warfare detectors
by: nextdouble 07/25/05 08:31 am
Msg: 8951 of 8958
American Access Technologies, Inc. (NASDAQ: AATK) is pleased to report that it has received another order as a subcontractor of parts for specialized chemical warfare alarms for the armed forces.
http://finance.yahoo.com/q?s=aatk
GEPT $7.80 premarket, will it keep going at the open? I always seem to jump off the train too soon! LOL! Oh well, can't ever go broke taking a profit.